Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study

Table 1 Comparison of the two groups by preoperative and intraoperative characteristics

Factor	Isolyte-M® group (n:100)	Voluven® 6% group (n:100)	p value*
	Mean ± SD	Mean ± SD
Age	61.81 ± 10.12	61.52 ± 9.29	0.833
BMI (kg/m²)	27.88 ± 3.96	29.02 ± 4.61	0.063
LVEF (%)	53.72 ± 10.81	52.33 ± 11.08	0.370
Cross-clamp time (min)	53.57 ± 20.12	55.58 ± 17.22	0.449
CPB time (min)	79.69 ± 27.93	82.57 ± 23.98	0.435
Graft #	3.22 ± 1.06	3.10 ± 0.90	0.390
	n:%	n:%	p value**
Patient Total	100	100
Male sex	77	74	0.622
Current/Ex-smoker	67	63	0.553
Diabetes Mellitus	46	42	0.569
Hypertension	65	62	0.659
Dyslipidemia	79	76	0.611
Preoperative β-blocker use	40	47	0.318
Peripheral Arterial Disease^a	1	6	0.118***
Stroke	-	1	1.000***
Carotid Disease^b	7	5	0.552***
COPD/Asthma	14	15	0.841

*independent samples t-test.
**chi-square test.
***Fisher’s exact test.
^aHistory of therapeutic vascular intervention, history of claudication, angiography/non-invasive proven peripheral arterial disease.
^bHistory of carotid intervention or angiographic/non-invasive proven >40% stenosis of either carotid.
BMI: body mass index, LVEF: left ventricular ejection fraction.
CPB: cardiopulmonary bypass, COPD: chronic obstructive pulmonary disease.

ISSN: 1749-8090